References

Aaby P, et al. Long-term survival after Edmonston-Zagreb measles vaccination: Increased female mortality. Journal of Pediatrics 1993a;122:904–908.

Aaby P, Andersen M, Knudsen K. Excess mortality after early exposure to measles. International Journal of Epidemiology 1993b; 22:156–162.

Aaby P, Bukh J, Kronborg D, Lisse IM, Da Silva MS. Delayed excess mortality after exposure to measles during the first six months of life. American Journal of Epidemiology 1990a;132:211–219.

Aaby P, Seim E, Knudsen K, Bukh J, Lisse IM, Da Silva MC. Increases in postperinatal child morality among children of mothers exposed to measles during pregnancy. American Journal of Epidemiology 1990b;132:531–539.

Adenyi-Jones SC, Faden H, Ferdon MB, et al. Systemic and local immune responses to enhanced-potency inactiviated poliovirus vaccine in premature and term infants. Journal of Pediatrics 1992;120:686–689.

American Academy of Pediatrics (Committee on Infectious Diseases). Red Book. 23rd ed. Elk Grove Village, Ill.: Author, 1994:36–37.

Astbury J, Orgill A, Bajuk B. Relationship between two-year behavior and outcome at five years of very low birthweight survivors . Developmental and Child Neurology 1987;29:370–379.


Bernbaum J, Daft A, Samuelson J, et al. Half-dose immunization for diphtheria, tetanus, pertussis: Response of preterm infants. Pediatrics 1989;83:471–476.

Bertley FM, Ibrahim SA, Hoskins E, Ward BJ. Long-term follow-up of Haitian recipients of high-titer measles vaccines: No evidence of immunologic injury. Submitted; 1997.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 51
Vaccine Safety Forum: Summaries of Two Workshops References Aaby P, et al. Long-term survival after Edmonston-Zagreb measles vaccination: Increased female mortality. Journal of Pediatrics 1993a;122:904–908. Aaby P, Andersen M, Knudsen K. Excess mortality after early exposure to measles. International Journal of Epidemiology 1993b; 22:156–162. Aaby P, Bukh J, Kronborg D, Lisse IM, Da Silva MS. Delayed excess mortality after exposure to measles during the first six months of life. American Journal of Epidemiology 1990a;132:211–219. Aaby P, Seim E, Knudsen K, Bukh J, Lisse IM, Da Silva MC. Increases in postperinatal child morality among children of mothers exposed to measles during pregnancy. American Journal of Epidemiology 1990b;132:531–539. Adenyi-Jones SC, Faden H, Ferdon MB, et al. Systemic and local immune responses to enhanced-potency inactiviated poliovirus vaccine in premature and term infants. Journal of Pediatrics 1992;120:686–689. American Academy of Pediatrics (Committee on Infectious Diseases). Red Book. 23rd ed. Elk Grove Village, Ill.: Author, 1994:36–37. Astbury J, Orgill A, Bajuk B. Relationship between two-year behavior and outcome at five years of very low birthweight survivors . Developmental and Child Neurology 1987;29:370–379. Bernbaum J, Daft A, Samuelson J, et al. Half-dose immunization for diphtheria, tetanus, pertussis: Response of preterm infants. Pediatrics 1989;83:471–476. Bertley FM, Ibrahim SA, Hoskins E, Ward BJ. Long-term follow-up of Haitian recipients of high-titer measles vaccines: No evidence of immunologic injury. Submitted; 1997.

OCR for page 51
Vaccine Safety Forum: Summaries of Two Workshops Bertley FM, Ibrahim SA, Hoskins E, Ward BJ. Long-term follow-up of Sudanese recipients of high-titer measles vaccines: No evidence of immunologic injury. Submitted; 1997. Bryson SE. Brief report: Epidemiology of autism. Journal of Autism and Developmental Disorders 1996; 26:165–167. Centers for Disease Control and Prevention (CDC). Pertussis immunization: Family history of convulsions and use of antipyretics—supplementary ACIP statement. MMWR 1987; 36;281–282. CDC. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(No. RR-9):9. Chen R, Kent J, Rhodes P, et al. Investigation of a possible association between influenza vaccination and GBS in the U.S., 1990–1991 (abstract). Postmarketing Surveillance 1992; 6:5–6. Chen RT, Haber P, Mullen JR, Haber M. Reexamination of Family History of Convulsions—A Risk Factor for Neurologic Events after DTP Vaccination. Paper presented at American Public Health Associations' 121st Meeting, San Francisco, November 1993. Chen RT, Weierbach R, Bisoffi Z, et al. A "post-honeymoon period" measles outbreak in Myinga Sector, Burundi. International Journal of Epidemiology 1994; 23:185–193. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annual Review of Immunology 1996; 13:29–60. Conway S, James J, Balfour A, et al. Immunization of the preterm baby [see comments]. Journal of Infectious Diseases 1993; 27:143–150. D'Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 1995; 96(1, Pt. 1):18–22. Education Department. Eighteenth annual report to Congress on the implementation of the Individuals with Disabilities Education Act, December 1996 (SER, Dec. 25, 1996). Fujinami RS, Oldstone MBA. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity. Science 1985; 230:1043–1045. Garenne M, et al. Child mortality after high-titer measles vaccines: Prospective study in Senegal. Lancet 1991; 338:903–907. Goldenthal KL, Burns DL, McVittie LD, Lewis BP, Williams JC. Vaccines and simultaneous administration (conference overview). Annals of the New York Academy of Sciences 1995; 754:xi–xii. Gupta S, Sggarway S, Heads C. Brief report: Dysregulated immune system in children with autism. Beneficial effects of intravenous immune globulin on

OCR for page 51
Vaccine Safety Forum: Summaries of Two Workshops autistic characteristics. Journal of Autism and Developmental Disorders 1996;26:439–452. Haraguchi S, Good R, Day N. Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunology Today 1995; 16:595–603. Herroelen L, de Keyeser J, Ebinger G. Central nervous system demyelination after immunization with recombinant hepatitis B vaccine. Lancet 1995; 338:1174–1175. Holt E, et al. Differential mortality by measles vaccine titer and sex. Journal of Infectious Diseases 1995; 169:1087–1096. Hull HF, Williams PJ, Oldfield F. Measles mortality and vaccine efficacy in rural west Africa. Lancet 1983; 972–975. Hurwitz ES, Schonberger LB, Nelson DB, et al. Guillain-Barré syndrome and the 1978–1979 influenza vaccine. New England Journal of Medicine 1981; 304: 1557–1561. Institute of Medicine (IOM). Adverse Effects of Pertussis and Rubella Vaccines. Washington, D.C.: National Academy Press, 1991. IOM. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, D.C.: National Academy Press, 1994a. IOM. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington, D.C.: National Academy Press, 1994b. IOM. Research Strategies for Assessing Adverse Events Associated with Vaccines: A Workshop Summary. Washington, D.C.: National Academy Press , 1994c. IOM. Options for Poliomyelitis Vaccination in the United States: Workshop Summary. Washington, D.C.: National Academy Press, 1996. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. New England Journal of Medicine; 1995; 332:1262–1266. Kaplan JE, Katona P, Hurwitz ES, et al. Guillain-Barré Syndrome in the United States, 1979–1980 and 1980–1981. JAMA 1982; 248:698–700. Koblin BA, Townsend TR, Munoz A, et al. Response of preterm infants to diphtheria-tetanus-pertussis vaccine. Pediatric Infectious Disease Journal 1988; 7:704–711. Kurland LT, Wiederhold WC, Kirkpatrick JW, et al. Swine influenza vaccine and Guillain-Barré syndrome. Epidemic or artifact? Archives of Neurology 1985; 42:1089–90. Kurtzke JF. The epidemiology of MS. In: Raine CS, McFarland HF, Tourtellotte W, eds. Multiple Sclerosis: Clinical and Pathogenetic Basis. 2nd ed. New York: Chapman & Hall, 1997.

OCR for page 51
Vaccine Safety Forum: Summaries of Two Workshops Leon M, et al. Immunologic parameters two years after high-titer measles immunization in Peruvian children. Journal of Infectious Diseases 1993; 168:1097–1104. Libman M, Ward BJ, Bertley FM, Hoskins E, Ibrahim SA. Prospective study of high-titer vaccines in the Sudan: No evidence of increased morbidity after vaccination. Submitted; 1997. Love LA, and Miller FW. Non-infectious environmental agents associated with myopathy. Current Opinions in Rheumatology 1993; 5:712–718. Michielsens B, Wilms G, Marchal G, et al. Serial magnetic resonance imaging studies with paramagnetic contrast medium: Assessment of disease activity in patients with multiple sclerosis before and after influenza vaccination. European Neurology 1990; 30:258–259. Miller AE, Morgante LA, Buchwald LY, et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997; 48:312–314. Miller FW. Genetics of autoimmune diseases. Experimental and Clinical Immunogenetics 1995; 12:182–190. Miller FW. Genetics of environmentally-associated rheumatic diseases. In Rheumatic Diseases and the Environment, Kaufman L and Varga J, eds. New York: Chapman & Hall, 1997. Miller JFAP, Morahan G, Allison J. Extrathymic acquisitions of tolerance by T lymphocytes. Cold Spring Harbor Symposium on Quantitative Biology 19898; LIV:807–813. Munoz A, Savador A, Brodsky NL, et al. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics 1995; 96:216–219. Murphy WH, Nawrocki J, Pease L. Age-dependent paralytic viral infection in C58 mice: Possible implications in human neurologic disease. Progress in Brain Research 1983; 9:291–303. Nadler NS. Multiple sclerosis and hepatitis B vaccination (letter). Clinics in Infectious Disease 1993; 17:928–929. Nichols PI, Chen TC. Minimal Brain Dysfunction: A Prospective Study. Hillsdale, N.J.: Erlbaum, 1981. Peeler RN, Cluff LE, Trever RW. Hyper-immunization of man. Bulletin of Johns Hopkins Hospital 1958; 103:183–198. Peeler RN, Kadull PJ, Cluff LE. Intensive immunization of man. Evaluation of possible adverse consequences. Annals of Internal Medicine 1965; 63:44–57. Pogue GP, Hofmann J, Duncan R, Best J, Etherington J, Sontheimer RD, et al. Autoantigens interact with cis-acting elements of rubella virus RNA. Journal of Virology 1996;70:6269–6277.

OCR for page 51
Vaccine Safety Forum: Summaries of Two Workshops Ramsay MD, Miller E, Ashworth LA, et al. Adverse events and antibody response to accelerated immunization in term and preterm infants. Archives of Diseases in Childhood 1995; 72:230–232. Ropper AH. The Guillain-Barré syndrome. New England Journal of Medicine 1992; 326:1130. Root-Bernstein RS. Multiple-antigen-mediated autoimmunity (MAMA) in AIDS: A possible model for post-infectious autoimmune complications. Research in Immunology 1990; 141:321–339. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976–1977. American Journal of Epidemiology 1991; 133:940–951. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. Journal of Allergy and Clinical Immunology 1995;96:563–565. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. American Journal of Epidemiology 1979; 110;105–123. Sela M, Arnon R. Synthetic approaches to vaccines for infectious and autoimmune diseases. Vaccine 1992;10:991–999. Shaw FE Jr, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. American Journal of Epidemiology 1988; 127:337–352. Sibley WA. Risk factors in multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte W, eds. Multiple Sclerosis: Clinical and Pathogenetic Basis. New York: Chapman & Hall, 1997. Singh NK, Atreya CD, Nakhasi HL. Identification of calreticulin as a rubella virus RNA binding protein. Proceedings of the National Academy of Sciences United States of America 1994; 91:12770–12774. Slater P, Ben-Zvi T, Fogel A, Ehrenfeld M, Ever-Hadani S. Absence of an association between rubella virus vaccination and arthritis in underimmune postpartum women. Vaccine 1995; 13:1529–1532. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and age. Neurology 1995; 45:1122–1126. Sudhakarow L, O'Brien K, Nieuwhof. Routine immunization of extremely premature infants is associated with significant adverse events (abstract). (American Association of Pediatricians, Boston Meeting 1996).

OCR for page 51
Vaccine Safety Forum: Summaries of Two Workshops Urnovitz HB, Murphy WH. Human endogenous retroviruses: Nature, occurrence and clinical implications in human disease. Clinical Microbiology Reviews 1996; 9:72–99. Urnovitz HB, Murphy WH, Gottfried TD, and Friedman-Kien, AE. Urine-based diagnostic technologies. Trends in Biotechnology 1996; 14:361–364. Ventura SJ, Martin JA, Mathews TJ, et al. Advance report of final natality statistics, 1994. Monthly vital statistics report; 44(11) Suppl. Hyattsville, Md.: National Center for Health Statistics, 1996. Vergelli M, Hemmer B, Utz U, et al. Differential activation of human autoreactive T-cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99). European Journal of Immunology 1996; 26:2624–2634. Vogt AB, Kropshofer H, Kalbacher H, et al. Ligand motifs of HLS-DRB5 *0101 and DRBI*1501 molecules delineated from self-peptides. Journal of Experimental Medicine 1994; 153:1665–1673. Waisbren BA. Other side of the coin (letter). Infectious Disease News 1992; 5:2. Warkany J. Congenital Anomalies: Notes and Comments. Chicago: Year Book Medical Publishers , 1971. Westall FC, Root-Bernstein RS. An explanation of prevention and suppression of experimental allergic encephalomyelitis. Molecular Immunology 1983; 20:169–177. White CS, Adler WH, McGann VG. Repeated immunization: Possible adverse effects. Reevaluation of human subjects at 25 years. Annals of Internal Medicine 1974; 81:594–600. Wucherpfennig KW, Wette A, Southwood S, et al. Structural requirements for the binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T-cell clones. Journal of Experimental Medicine 1994; 179;279–290. Zhang J, Markovic S, Lacet B, et al. Increased frequency of IL2 responsive T-cells specific for myelin basic protein and preteolipid protein in peripheral blood and cerebrospinal fluid of patients with Multiple sclerosis. Journal of Experimental Medicine 1994; 179:973–984.